3030 Callan Road
8 articles with Ansun Biopharma
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Ansun Biopharma, Inc., today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
Ansun Biopharma is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral infections,
Ansun is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections.
Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181.
Ansun BioPharma Announces Two Publications Showing Inhibitory Effects Of DAS181 On Respiratory Syncytial Virus (RSV) And Human Metapneumovirus (hMPV)